Rapid Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in HIV-Infected Patients. Comparison of LED Fluorescent Microscopy and the GeneXpert MTB/RIF Assay in a District Hospital in India

Gerardo Alvarez-Uria, Jose M Azcona, Manoranjan Midde, Praveen K Naik, Srinivasulu Reddy, Raghuprakash Reddy, Gerardo Alvarez-Uria, Jose M Azcona, Manoranjan Midde, Praveen K Naik, Srinivasulu Reddy, Raghuprakash Reddy

Abstract

HIV-related tuberculosis is difficult to diagnose and is associated with high morbidity and mortality. Recently, the World Health Organization has endorsed the GeneXpert MTB/RIF (Xpert) assay for the diagnosis of pulmonary tuberculosis in HIV-infected patients from developing countries, but information about the use of Xpert for the diagnosis of extrapulmonary tuberculosis is scarce. In this study, we compared the performance of light-emitting diode (LED) auramine fluorescent microscopy and the Xpert assay for the diagnosis of tuberculosis in HIV infected patients in a district hospital of India. Although at higher cost, Xpert outperformed LED fluorescent microscopy in all type of specimens, especially in cerebrospinal fluid where the number of positive results was increased 11 times. Pleural fluid, ascitic fluid, pus, and stool specimens also yielded positive results with the Xpert assay. When collecting two additional early-morning sputum samples, the increase of the number of positive results with the Xpert assay was lower than previously reported for HIV infected patients. Rifampicin resistance was observed in 2.2% of the cases. The results of this study show that the Xpert assay can dramatically improve the rapid diagnosis of tuberculous meningitis and other types of extrapulmonary tuberculosis of HIV infected patients.

References

    1. World Health Organization. Global Tuberculosis Control. World Health Organization; 2011.
    1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine. 2003;163(9):1009–1021.
    1. Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. The Lancet. 2007;369(9578):2042–2049.
    1. World Health Organization. Rapid Implementation of the Xpert MTB/RIF Diagnostic Test. World Health Organization; 2011.
    1. World Health Organization. Fluorescent Light-Emitting Diode (LED) Microscopy for Diagnosis of Tuberculosis. World Health Organization; 2011.
    1. Marais BJ, Brittle W, Painczyk K, et al. Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clinical Infectious Diseases. 2008;47(2):203–207.
    1. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and Rifampicin resistance: Xpert MTB/RIF system. Policy Statement. 2011
    1. Kingkaew N, Sangtong B, Amnuaiphon W, et al. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. International Journal of Infectious Diseases. 2009;13(6):722–729.
    1. Alvarez-Uria G, Midde M, Pakam R, Naik PK. Gender differences, routes of transmission, socio-demographic characteristics and prevalence of HIV related infections of adults and children in an HIV cohort from a rural district of India. Infectious Disease Reports. 2012;4(2, article e19)
    1. World Health Organization. Reduction of Number of Smears for the Diagnosis of Pulmonary TB. World Health Organization; 2007.
    1. World Health Organization. Standard operating procedure for auramine staining, Module 27.
    1. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. Journal of Clinical Microbiology. 2010;48(1):229–237.
    1. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? Journal of Clinical Microbiology. 2011;49(7):2540–2545.
    1. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV medicine association of the infectious diseases society of America. Morbidity and Mortality Weekly Report, Recommendations and Reports. 2009;58(4):1–207.
    1. Small PM, Pai M. Tuberculosis diagnosis—time for a game change. The New England Journal of Medicine. 2010;363(11):1070–1071.
    1. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. American Family Physician. 2005;72(9):1761–1768.
    1. Parsons LM, Somoskövi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical Microbiology Reviews. 2011;24(2):314–350.
    1. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British infection society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. Journal of Infection. 2009;59(3):167–187.
    1. Whalen C, Horsburgh CR, Jr., Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-assosiated truberculosis. AIDS. 1997;11(4):455–460.
    1. Kourbatova EV, Leonard MK, Jr., Romero J, Kraft C, del Rio C, Blumberg HM. Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US. European Journal of Epidemiology. 2006;21(9):715–721.
    1. Lawson L, Yassin MA, Ramsay A, Emenyonu NE, Squire SB, Cuevas LE. Comparison of scanty AFB smears against culture in an area with high HIV prevalence. International Journal of Tuberculosis and Lung Disease. 2005;9(8):933–935.
    1. van Deun A, Salim AH, Cooreman E, et al. Scanty AFB smears: what’s in a name? International Journal of Tuberculosis and Lung Disease. 2004;8(7):816–823.
    1. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. European Respiratory Journal. 2012;40(2):442–447.
    1. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Medicine. 2011;8(7)e1001067

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться